ContraBand system logo

Revolution In Heart Failure

Restore Medical has developed the first and only transcatheter Pulmonary Artery Banding  (PAB) system for the treatment of HFrEF patients

ContraBand™ is an innovative and reversible therapy for the treatment of left ventricle (LV) failure. The catheter-delivered implant is designed to leverage the right ventricle (RV) to provide support to the LV, improving LV ejection fraction and restoring optimal ventricular geometry. With no approved treatments currently available for this condition, ContraBand™ has the potential to transform the way congestive heart failure (CHF) patients are treated.

Ongoing Clinical trial have demonstrated that ContraBand™ is a highly effective and safe treatment for patients with LV failure. The implantation procedure for ContraBand™ is simple and time effective. 

Value proposition

Fully reversible

Fully reversible

Time effective

Time effective

Restore the favorable left ventricular geometry

Restore the favorable left ventricular geometry

Improve patients’ quality of life

Improve patients’ quality of life

About

Restore Medical is dedicated to improve the treatment of congestive heart failure (CHF) by developing innovative and disruptive medical device that will reduce hospitalizations, mortality, and morbidity.

Management Team

Gilad Marom

CEO

Stephen Bellomo

CTO and Co-Founder

Aida Bibliowicz

VP of Clinical Affairs

Elchanan Brukheimer, MBBS

Co-Founder & CMO

Eyal Lifschitz

Chairman of the Board of Directors

SAB

Elazer Edelman, MD

Sean Pinney, MD

Dr. Martin Leon

Shmuel Banai, MD

Offer Amir, MD

Stefan Verheye, MD

News & Media

Restore Medical Announces Successful First-In-Human Preliminary Results of Its CONTRABAND™ System for Symptomatic Systolic Heart Failure Patients

Restore Medical, a privately held medical device company, has successfully completed enrollment of the First In Human clinical study with its CONTRABAND™ device for Symptomatic Systolic Heart Failure Patients.

Restore Medical secures €2.5 million in EU funding for cardiac implants to treat heart failure

The Israeli company will receive an additional equity investment of €10 million from the European Innovation Council subject to a future milestone

Restore Medical Announces First in Human Trial for Treatment of Heart Failure in Patients

ContraBand™ technology helps restore the heart’s functionality and may significantly improve patients’ quality of life

Gilad Marom

CEO

As CEO of Restore Medical, Gilad Marom brings more than 20 years of experience in medical device development to the company. Prior to joining Restore Medical, Gilad held executive positions at Edwards Lifesciences in both Israel and Irvine, USA, where he successfully oversaw the development of three cardiovascular implants from inception to clinical success.

Stephen Bellomo

CTO and Co-Founder

Stephen brings over 20 years of experience in medical device development to Restore Medical. He has held leadership positions as Vice President of R&D, Vice President of Clinical Affairs, and Chief Technology Officer in several medical device and biotech companies.

Aida Bibliowicz

VP of Clinical Affairs

Aida  brings over 20 years of experience in clinical development to her role as Vice President of Clinical Affairs at Restore Medical. Prior to joining the company, Aida served as VP Clinical Affairs at several companies where she successfully led the development of new drug treatments, achieving marketing approval in the US. With her expertise in clinical development and regulatory affairs, Aida plays a critical role in ensuring that Restore Medical’s technologies are clinically safe and effective, and meet regulatory requirements.

Elchanan Brukheimer, MBBS

Co-Founder & CMO

Dr. Bruckheimer is the Director of the Cardiac Catheterization Laboratories at Schneider Children’s Medical Center, Israel. He received his medical degree from the University of London, specialized in General Pediatrics at the Shaarei Zedek Medical Center, Jerusalem and later specialized in Pediatric Interventional Cardiology at Yale University, USA. Dr. Bruckheimer is a leading expert on 3D imaging and interventional cardiology for the treatment of congenital and structural heart disease and serves regularly on faculty at leading international meetings including TCT (Transcatheter Cardiovascular Therapeutics), PICS-AICS, CSI, ICI and the Veith symposium.

Eyal Lifschitz

Chairman of the Board of Directors

Eyal Lifschitz is Co-founder & Managing General Partner at Peregrine Ventures, a global life science venture capital fund dedicated to improving patients’ quality of life by investing in and supporting life-changing healthcare opportunities.

Eyal is an entrepreneur and investor with years of experience in establishing and managing life science companies and their business development efforts

Elazer Edelman, MD

Elazer Edelman, MD, PhD is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital. Prof. Edelman directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC). Prof. Edelman holds an MD from Harvard Medical School, PhD in Medical Engineering and Medical Physics from MIT, MS degree in Electrical Engineering and Computer Sciences from MIT, and BS in Bioelectrical Engineering and in Applied Biology from MIT.

Sean Pinney, MD

Sean Pinney is Professor of Medicine, Philip J. and Harriet L. Goodhart Chief of Cardiology and Associate Director of Cardiovascular Clinical Institute at Mount Sinai Morningside. Dr. Pinney is an active clinical researcher who has led both NIH and industry-sponsored trials in the areas of heart failure, cardiac transplantation and mechanical circulatory support. He serves on the editorial boards of JACC, JACC Heart Failure, the Journal of Heart & Lung Transplantation and the Journal of Cardiac Failure. He serves on the AST Board of Directors, is a member of the Georgetown Medical Alumni Board and is past President of the New York Cardiothoracic Transplant Consortium.

Dr Martin Leon

Dr. Martin Leon

Martin B. Leon, MD, is the Mallah Family Professor of Cardiology at the Columbia University Irving Medical Center College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy (CIVT) at New York-Presbyterian Hospital/Columbia University Medical Center. Previously, Dr. Leon was also the Director of the Cardiac Catheterization Laboratories at New York-Presbyterian Hospital/Columbia University Medical Center and currently he also serves on the Executive Board of the New York-Presbyterian/Columbia Heart Valve Center. Dr. Leon was the Founder of Transcatheter Cardiovascular Therapeutics (TCT) symposium and Chairman Emeritus of the Cardiovascular Research Foundation (CRF) in New York City and is currently CRF’s Co-Director, Medical Research and Education Division. A distinguished pioneer in interventional cardiovascular medicine, Dr. Leon has been the national principal investigator for over 75 clinical trials that have helped shape the field including STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, RESOLUTE. He has co-authored over 2,000 peer reviewed scientific publications and abstracts, which have appeared in the most prestigious medical journals. As a practicing interventional cardiologist, Dr. Leon has performed over 10,000 procedures during his career. 

Shmuel Banai, MD

Prof. Banai is the Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel. He is a full academic Professor of Cardiology at the Tel Aviv University, Sackler School of Medicine. Head, of the Nicholas and Elizabeth Slezak Super Center for Cardiac Research and Biomedical Engineering, and the Walton Chair of Interventional Cardiology at the Tel Aviv University. Prof. Banai is the author of more than 200 peer-reviewed papers and book chapters and has participated in many clinical and pre-clinical research studies in the field of cardiology, interventional cardiology, and pharmacotherapy.

Offer Amir, MD

Prof. Offer Amir, MD, FACC, FESC is the Director of the Heart Institute, Hadassah Medical Center in Jerusalem and a Professor of Cardiovascular Medicine at the Hadassah-Hebrew University. Prof. Amir is a board member of the Heart Failure Association of the ESC (HFA) and was the president of the Israel Heart Society.

Stefan Verheye, MD

Dr. Stefan Verheye, MD, PhD, is a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. Dr. Verheye is the author of over 150 peer-reviewed journals, ten book chapters, over 400 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease.

Skip to content